To include your compound in the COVID-19 Resource Center, submit it here.

Eisai exercises option for Biogen's anti-beta amyeloid mAb

Eisai Co. Ltd. (Tokyo:4523) exercised an option to co-develop and co-promote aducanumab (BIIB037) from Biogen Inc. (NASDAQ:BIIB). The industry has kept a close watch on the human

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE